Research and Markets has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2016" report to their offering.
'Cystic Fibrosis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies
'Cystic Fibrosis - Pipeline Review, H2 2016'; Cystic Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 121 molecules are developed by Companies and remaining by the Universities/Institutes.
It also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 20, 22, 52 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 6, 6 and 1 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/4d8qd3/cystic_fibrosis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005491/en/Business Wire
Last updated on: 28/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.